News · 26 weeks55-11%
2026-03-012026-08-23
Mix2990d
- SEC Filings12(41%)
- Other10(34%)
- Insider5(17%)
- Leadership1(3%)
- Analyst1(3%)
Latest news
25 items- INSIDERInterim CFO Farag Kameel D. was granted 1,728 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 8% to 23,309 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics Builds Momentum for AKTX-101 with Compelling Urothelial Cancer Data Supporting Differentiated ADC StrategyAKTX-101 demonstrated robust anti-tumor activity across multiple clinically relevant urothelial cancer preclinical models Data supports the potential of Akari’s novel PH1 RNA spliceosome-modulating payload to overcome payload-specific resistance Results strengthen the rationale for a differentiated ADC sequencing strategy as ADC use expands across oncology and more patients require treatment following relapse Akari advancing IND-enabling activities for AKTX-101 toward planned Phase 1 clinical development in mid-2027 TAMPA, Fla. and LONDON, Aug. 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADC
- PRAkari Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Progress of AKTX-101 Towards Phase 1 and Strategic Collaboration for Its ADC Payload PlatformAKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic investors TAMPA, Fla. and LONDON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel
- SECAkari Therapeutics plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form 10-Q filed by Akari Therapeutics plc10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form SCHEDULE 13G filed by Akari Therapeutics plcSCHEDULE 13G - Akari Therapeutics Plc (0001541157) (Subject)
- INSIDERInterim CFO Farag Kameel D. was granted 1,130 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 6% to 21,581 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- PRAkari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC InnovationDiscussion explores how combining complementary payload technologies may unlock new therapeutic opportunities while reinforcing the versatility of Akari's proprietary PH1 spliceosome-modulating payload platform Access the Akari CEO Corner here TAMPA, Fla. and LONDON, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing the Company's recently announced strategic research collaboration with WhiteHawk Therapeutics and why the Company b
- PRAkari Therapeutics CEO Explains Why Growing Industry Demand for Next-Generation ADC Payloads Positions the Company at the Center of a Major Oncology OpportunityVirtual Investor "What This Means" segment highlights strategic Whitehawk collaboration, accelerating industry validation of novel ADC payloads, and Akari's differentiated PH1 platform Watch the "What This Means" video here TAMPA, Fla. and LONDON, July 22, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today that announced that its CEO, Abizer Gaslightwala, participated in a Virtual Investor "What This Means" interview focused on the Company's recently announced strategic research collaboration with Whitehawk Therapeutics. During the interview, Mr. Ga
- PRAkari Therapeutics Enters Strategic Research Collaboration with Whitehawk TherapeuticsTAMPA, Fla. and LONDON, July 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced a strategic research collaboration with Whitehawk Therapeutics, a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved ADC cancer treatments. Under the collaboration, the companies will conduct a series of focused preclinical studies evaluating Akari's proprietary PH1 spliceosome-modulating payload technology in combination with Whitehawk’s topoisomerase I inhibitor (TOP1i) ADC
- ANALYSTAkari Therapeutics upgraded by Maxim Group with a new price targetMaxim Group upgraded Akari Therapeutics from Hold to Buy and set a new price target of $30.00
- INSIDERDirector Patel Samir Rashmikant exercised 22,474 units of American Depositary Shares representing Ordinary Shares at a strike of $0.43 (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- SECSEC Form EFFECT filed by Akari Therapeutics plcEFFECT - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-3/A filed by Akari Therapeutics plcS-3/A - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-3/A filed by Akari Therapeutics plcS-3/A - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form EFFECT filed by Akari Therapeutics plcEFFECT - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Appoints Former AACR President and Renowned Oncology Drug Development Leader, Patricia LoRusso, D.O., to Scientific Advisory BoardGlobally recognized leader in early-phase oncology clinical development and experimental therapeutics Strengthens strategic expertise as Akari advances its novel ADC payload that modulates RNA splicing into future Phase 1 First-in-Human trial TAMPA, Fla. and LONDON, July 07, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the appointment of Patricia LoRusso, D.O. to its Scientific Advisory Board. "Dr. LoRusso is one of the most influential leaders in oncology drug development, and her appointment represents a significant addition to Aka
- SECAkari Therapeutics plc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form S-3 filed by Akari Therapeutics plcS-3 - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Completes Previously Announced PIPE, Strengthening Balance Sheet Ahead of Potential Key Clinical and Regulatory MilestonesTAMPA, Fla. and LONDON, June 29, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the completion of its previously announced PIPE through the consolidation of the remaining scheduled investment closings into a single funding event. Combined with warrant exercises completed in May, the Company received approximately $8.3 million in total capital during Q2 2026. "We appreciate the decision of our investor group to complete the remaining funding earlier than originally scheduled, and for some of these investors to further increase their commi
- SECSEC Form 8-K filed by Akari Therapeutics plc8-K - Akari Therapeutics Plc (0001541157) (Filer)
- SECAmendment: SEC Form S-1/A filed by Akari Therapeutics plcS-1/A - Akari Therapeutics Plc (0001541157) (Filer)
- INSIDERInterim CFO Farag Kameel D. was granted 18,830 units of American Depositary Shares representing Ordinary Shares, increasing direct ownership by 1,161% to 20,452 units (SEC Form 4)4 - Akari Therapeutics Plc (0001541157) (Issuer)
- INSIDERSEC Form 4 filed by CEO Gaslightwala Abizer4 - Akari Therapeutics Plc (0001541157) (Issuer)
- SECSEC Form SCHEDULE 13G filed by Akari Therapeutics plcSCHEDULE 13G - Akari Therapeutics Plc (0001541157) (Subject)
AKTX FAQ
6 questionsWhat does Akari Therapeutics plc do?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in...Where does AKTX stock trade?
Akari Therapeutics plc (AKTX) is listed on NASDAQ.What sector and industry is AKTX in?
Akari Therapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AKTX?
Akari Therapeutics plc has had 4 recent analyst actions on file. The most recent action was from Maxim Group: Buy with a $3000.00 price target on 2026-07-20.What companies are similar to AKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare AKTX side-by-side with any of them on Quantisnow.How can I track AKTX on Quantisnow?
Quantisnow aggregates Akari Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKTX to receive live email and push alerts on every new disclosure.